soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results NEJM Editorial Fellow Harleen Marwah,
Pay in 4 interest-free payments of $5.87 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12



![View Clearinghouse copy of document [PDF]](https://img.yumpu.com/9233544/1/500x640/view-clearinghouse-copy-of-document-pdf.jpg)




















